Published • loading... • Updated
Eli Lilly Advances Oral GLP‑1 With Strong Phase 3 Data in Type 2 Diabetes
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Eli Lilly Advances Oral GLP‑1 With Strong Phase 3 Data in Type 2 Diabetes
As reported on BioSpace, Eli Lilly is moving closer to expanding the use of its oral GLP‑1 receptor agonist orforglipron, marketed as Foundayo, into type 2 diabetes (T2D), following encouraging results from multiple late-stage clinical trials. The company plans to submit the therapy for regulatory approval in T2D after demonstrating consistent improvements in blood glucose […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
